Hematologic Oncology | Specialty

Diagnosing Waldenstrom Macroglobulinemia

March 4th 2019

Dr. Gertz on the Outlook for Waldenstrom Macroglobulinemia

March 4th 2019

Morie A. Gertz, MD, MACP, discusses the current outlook for patients with Waldenström macroglobulinemia.

AML Management Evolving for Elderly Patients

March 3rd 2019

More options are available than ever before for treating older patients with acute myeloid leukemia and fresh hopes are resting on combinations of venetoclax plus hypomethylating agents.

Agents Emerging in Late Relapsed/Refractory Myeloma Space

March 3rd 2019

Sagar Lonial, MD, discusses some of the emerging agents for the treatment of patients with late relapse in multiple myeloma.

Jabbour Highlights Ongoing Research, Current Treatment for ALL Subtypes

March 2nd 2019

Elias Jabbour, MD, discusses the treatment options for patients with acute lymphoblastic leukemia across these various subgroups.

Making the Case for Earlier CAR T-Cell Therapy in Lymphoma

March 2nd 2019

Real-world data on the use of chimeric antigen receptor T-cell therapy in large B-cell lymphoma bear out the pivotal results from ZUMA-1 and demonstrate not only that the treatment approach is here, but also that it’s time to address issues of efficacy, safety, cost, and moving this approach into earlier lines of therapy.

Targeted Therapies Continue to Show Promise Against FLT3, IDH1/2 Mutations in AML

March 2nd 2019

Jorge E. Cortes, MD, discusses the current treatment options for patients with acute myeloid leukemia, including the use of quizartinib in patients with FLT3 mutations, as well as data from the QuANTUM-R trial.

Dr. Chari Discusses Frail and Elderly Patients With Multiple Myeloma

March 2nd 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses frail and elderly patients with multiple myeloma.

Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies

March 2nd 2019

Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.

Dr. Park on Challenges With CAR T-Cell Therapies in AML

March 1st 2019

Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.

Dr. Kambhampati on Ropeginterferon Alfa-2b in Myeloproliferative Neoplasms

February 28th 2019

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the use of ropeginterferon alfa-2b in myeloproliferative neoplasms (MPNs).

Pivotal Data Refine Treatment Strategies in Hodgkin Lymphoma and Follicular Lymphoma

February 27th 2019

Leo I. Gordon, MD, discussed these recent updates in Hodgkin lymphoma and non–Hodgkin lymphoma and pointed to research on the horizon.

Dr. Kiladjian on Ruxolitinib Plus Interferon in MPNs

February 27th 2019

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses a study of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasms.

Dr. Kambhampati Discusses Role of Interferon in MPNs

February 26th 2019

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon in the treatment of patients with myeloproliferative neoplasms.

Subcutaneous Daratumumab Succeeds in Phase III Myeloma Trial

February 26th 2019

A subcutaneous formulation of daratumumab is noninferior in inefficacy and pharmacokinetics compared with standard intravenous daratumumab in patients with relapsed/refractory multiple myeloma.

Iomab-B Shows Promise as Novel Conditioning for HSCT in AML

February 25th 2019

More than 90% of older patients with relapsed/refractory acute myeloid leukemia had successful engraftment of allogeneic hematopoietic stem cell transplant preceded by novel conditioning with an iodinated CD45-targeted antibody.

Dr. Lulla Discusses Post-Transplant Options for Leukemias

February 24th 2019

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

Thrombotic Microangiopathy a Threat After Hematopoietic Cell Transplant

February 23rd 2019

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

Dr. Verstovsek on Toxicity Profile of Ruxolitinib in MPNs

February 22nd 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.

Pretransplant MRD Prognostic for Outcomes in Adults With ALL

February 22nd 2019

Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.